Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
April 25, 2023 at 10:43 am
Share
Jiangxi Fushine Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 397.92 million compared to CNY 402.33 million a year ago. Revenue was CNY 397.92 million compared to CNY 402.33 million a year ago.
Net loss was CNY 30.15 million compared to net income of CNY 27.95 million a year ago. Basic loss per share from continuing operations was CNY 0.06 compared to basic earnings per share from continuing operations of CNY 0.05 a year ago. Diluted loss per share from continuing operations was CNY 0.06 compared to diluted earnings per share from continuing operations of CNY 0.05 a year ago.
Jiangxi Fushine Pharmaceutical Co., Ltd. is principally engaged in research and development, manufacturing and sales of bulk drugs, pharmaceutical intermediates and related products. The Company's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The Company distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.